Dependence of clot structure and fibrinolysis on apixaban and clotting activator
Background: Anticoagulants prevent the formation of potentially fatal blood clots. Apixaban is a direct oral anticoagulant that inhibits factor (F)Xa, thereby impeding the conversion of prothrombin into thrombin and the formation of blood clots. Blood clots are held together by fibrin networks that...
Saved in:
Main Authors: | Rebecca A. Risman, Mitali Shroff, Julie Goswami, Valerie Tutwiler |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-11-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037924003091 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tenecteplase: biochemical and clot lysis activity comparisons
by: Jan Bechmann, et al.
Published: (2024-12-01) -
Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism
by: Isabel Elías, et al.
Published: (2016-05-01) -
Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs
by: Alex M. Lynch, et al.
Published: (2024-11-01) -
A photodistributed rash in a patient on apixaban
by: Benjamin Donald Henson, BS, et al.
Published: (2025-01-01) -
Pharmacogenetic substantiation of personalized prescription of oral anticoagulants in clinical practice
by: K.I. Bentsionova, et al.
Published: (2023-03-01)